ERBB2 and breast carcinoma: The anti-proliferative activity of the trastuzumab reference standard (NIBSC-19/108) and various biosimilars of trastuzumab were evaluated using the resazurin (alamarBlue) proliferation inhibition assay in the HER2-positive breast cancer cell line of SKBR3.